M&A TRANSACTION · 2024
BioMatrix acquired by Frazier Healthcare Partners
$450.0M· 15.0x EBITDA
Target
BioMatrix
Acquirer
Frazier Healthcare Partners
Private Equity buyer
Disclosed financials at time of acquisition
Revenue
—
EBITDA
$30.0M
Deal Value
$450.0M
EV/EBITDA
15.0x
Context
This $450.0M acquisition of BioMatrix by Frazier Healthcare Partners sits in the pharmacy sub-vertical. The 15.0x EBITDA multiple paid in 2024 can be compared against the population median for pharmacy transactions of similar size on our Pharmacy valuation hub. Frazier Healthcare Partners is acquiring as a private equity buyer; see how PE acquirers typically price pharmacy businesses on our Pharmacy PE buyer-pool page.
Source
Data sourced from Press reporting / online presentations. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology
Value your own pharmacy
Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.
Compare your business to the BioMatrix acquisition.